
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is in a promising position with a strong financial performance and potential for growth due to its partnerships with top global pharmas and a focus on sustainability. However, potential risks, such as changes in regulations and the need for strong data security, should be closely monitored. Despite potential risks, Icon's solid track record and strategic initiatives make it a compelling investment opportunity.
Bears say
Icon is currently facing margin pressure due to higher-than-expected passthrough activity, which management has noted was stronger than anticipated and is now tracking above the original expectation of being roughly flat year-over-year. Additionally, Icon's exposure to large pharmaceutical clients and its efforts to prioritize and grow its presence in the mid-sized biotech space could lead to positive revenue momentum in the future. However, risks to the company's rating and share price include further accounting reviews or restatements, the potential for delays in delivering clinical trials, and the risk of data security breaches.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares